atara biotherapeutics

CRL, Atara

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is rated as a Buy.

Business Insider · 1d

Atara Biotherapeutics Faces Strategic Uncertainty Amid FDA Hold and CRL Issues

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence:

Reuters on MSN · 2d

US FDA puts clinical hold on Atara's trials for cancer cell therapies

Atara Biotherapeutics said on Tuesday the U.S. health regulator had placed a clinical hold on its trials for cancer cell therapies, sending the drug developer's shares down more than 4% in premarket trading.

Seeking Alpha on MSN · 2d

Atara extends losses after FDA clinical hold

Shares of Atara Biotherapeutics (NASDAQ:ATRA) continued to trade lower in the premarket on Tuesday after the U.S. Food and Drug Administration (FDA) slapped the cell therapy developer with a clinical hold,

Business Insider · 2d

Atara Biotherapeutics reports clinical hold placed on Ebvallo programs, ATA3219

Atara Biotherapeutics (ATRA) announced that the FDA has placed a clinical hold on Atara’s active investigational new drug, or IND,

Atara Biotherapeutics, Inc. Being Investigated on Behalf of Atara Biotherapeutics, Inc. Investors. Contact Levi & Korsinsky For Details

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Atara ...

FiercePharma2d

Atara's Ebvallo and pipeline candidate put on clinical hold in US after partner's failed plant inspection

After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...

BioSpace1d

FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets

The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...

Atara Biotherapeutics Faces Uncertainty Amid FDA Clinical Hold and Financing Needs, Resulting in Hold Rating

Atara Biotherapeutics (ATRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Benjamin ...

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...

The Pharma Letter1d

Clinical hold follows CRL for Atara

T-cell immunotherapy company Atara Biotherapeutics closed 8% lower on Tuesday, having lost 41% of its stock market value on ...

1don MSN

Stifel cuts Atara Biotherapeutics target to $5, holds rating

Stifel analysts adjusted their outlook on Atara Biotherapeutics (NASDAQ:ATRA) stock, reducing the price target to $5 from the previous $10, while maintaining a Hold rating on the shares. The decision ...

Atara's New Drug Applications Placed on Hold by FDA

Atara Biotherapeutics said the U.S. Food and Drug Administration placed a clinical hold on its active investigational new drug applications. The biotechnology company said the FDA put a hold on its ...

Zacks.com on MSN6d

ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate

Shares of Atara Biotherapeutics ATRA plunged 40.5% on Thursday after the FDA issued a complete response letter (CRL) against ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

CRL, Atara

Related topics